Jove
Visualize
お問い合わせ

関連する概念動画

Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

741
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
741
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
259
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

439
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
439
The Placebo Effect01:54

The Placebo Effect

6.3K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.3K
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  1. ホーム
  2. 新型抗うつ剤と抗がん剤のnuc01が,がんの生存者のうつ病に与える影響
  1. ホーム
  2. 新型抗うつ剤と抗がん剤のnuc01が,がんの生存者のうつ病に与える影響

関連する実験動画

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

174

新型抗うつ剤と抗がん剤のNuc01が,がんの生存者のうつ病に与える影響

Changchun Yuan1,2, Xudong Shi1, Zhiqiang Wang1

  • 1School of Chemistry and Chemical Engineering, North University of China, Taiyuan 030051, China.

Current issues in molecular biology
|August 27, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

新薬コンジュガットであるNuc01は,うつ病治療のトリプル再吸収阻害剤および潜在的な抗がん用途のライシン特異性デメチラーゼ1 (LSD1) 阻害剤として有望である.

キーワード:
LSD1 阻害剤PCPAデスヴェンラファクシン結合体抗がん剤抗うつ剤

さらに関連する動画

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.1K
The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

19.1K

関連する実験動画

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

174
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.1K
The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

19.1K

科学分野:

  • 薬理学について
  • 腫瘍学
  • 神経科学

背景:

  • がんから回復した患者のうつ病は,しばしばセロトニンおよびノルアピネフリン再吸収阻害剤 (SNRIs) で治療されます.
  • ライシン特異性デメチラーゼ1 (LSD1) は,がん細胞の増殖を抑制するので,がん治療の標的である.
  • 生存者のうつ病と癌の両方を 治療するための新しい戦略が必要です

研究 の 目的:

  • 新しいトランス-2フェニルcyclopropylamine (PCPA) 薬の結合体とvenlafaxineのプロドラッグのNuc01の潜在的二重治療用途を評価する.
  • うつ病のトリプル再吸収阻害剤としてのNuc01の有効性を調査する.
  • 抗がん性を持つLSD1阻害体としてのNuc01の可能性を評価する.

主な方法:

  • 抗うつ剤の可能性を評価するためにマウスの尻尾サスペンション試験を用いたin vivo試験.
  • Nuc01のLSD1への結合親和性とその抑制濃度 (IC50) を決定するインビトロ試験.
  • MDA-MB-231 がん細胞の増殖に対するNuc01の効果の評価

主要な成果:

  • デスメチルヴェンラファキシンより性能が優れ,強力なトリプル再吸収阻害を示唆した.
  • Nuc01は530nmのIC50でLSD1内のPCPA結合部位を効果的に占めていた.
  • Nuc01はMDA- MB-231がん細胞の増殖を阻害し,IC50は1130nmでした.
  • 結論:

    • Nuc01は二重機能を示し,うつ病の治療のための潜在的な三重再吸収阻害剤として作用する.
    • Nuc01は,抗がん性を持つLSD1阻害剤としての可能性を示しています.
    • Nuc01は,うつ病と癌の両方を治療するための有望な新しい治療薬です.